Page last updated: 2024-12-05

piperocaine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Piperocaine is a synthetic local anesthetic that was originally marketed as a topical anesthetic for ophthalmic surgery. It acts by blocking nerve conduction, preventing the transmission of pain signals. Its synthesis involves a multi-step process starting with the reaction of piperidine with chloroacetyl chloride. Piperocaine has been shown to have both anesthetic and vasoconstrictor properties, which makes it potentially useful for a variety of medical applications. It is a relatively potent local anesthetic and has been studied for its potential use in dentistry, ophthalmology, and dermatology. However, its clinical use has been limited due to its potential for toxicity, particularly in high doses. Research on piperocaine is ongoing to explore its potential as a therapeutic agent and to improve its safety profile.'

piperocaine: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10782
CHEMBL ID127865
CHEBI ID34925
SCHEMBL ID25713
MeSH IDM0079803

Synonyms (46)

Synonym
136-82-3
metycaine
piperocaine
1-piperidinepropanol, 2-methyl-, benzoate (ester), (.+/-.)-
neothesin
2-methyl-1-piperidinopropanol, benzoate
brn 0012274
(2-methylpiperidino)propyl benzoate
isocaine (iso-sol. co.) base
3-benzoxy-1-(2-methylpiperidino)propane
NCGC00167552-01
3-(2-methylpiperidin-1-yl)propyl benzoate
CHEMBL127865
isocaine base
chebi:34925 ,
unii-f66xui6gzl
piperocainum
einecs 205-262-1
piperocaine [inn:ban]
f66xui6gzl ,
piperocainum [inn-latin]
piperocainio
piperocaina [dcit]
5-20-04-00079 (beilstein handbook reference)
piperocainio [inn-spanish]
1-piperidinepropanol, 2-methyl-, benzoate (ester)
piperocaina
3-(2-methyl-1-piperidyl)propyl benzoate
1-piperidinepropanol, 2-methyl-, 1-benzoate
piperocaine [mi]
(+/-)-2-methyl-1-piperidinepropanol benzoate
.gamma.-(2-methylpiperidyl)propyl benzoate
(+/-)-3-benzoxy-1-(2-methylpiperidino)propane
2-methyl-1-piperidinepropanol benzoate
piperocaine [who-dd]
1-piperidinepropanol, 2-methyl-, benzoate (ester), (+/-)-
piperocaine [inn]
SCHEMBL25713
DTXSID8048315
3-(2-methyl-1-piperidinyl)propyl benzoate #
3-(2-methylpiperidino)propyl benzoate
2-methyl-1-piperidinepropanol, benzoate
1-piperidinepropanol, 2-methyl-, benzoate, (.+/-.)-
YQKAVWCGQQXBGW-UHFFFAOYSA-N
bdbm50225704
Q7197363
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.25890.035520.977089.1251AID504332
gemininHomo sapiens (human)Potency33.49830.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency25.09990.005612.367736.1254AID624044
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID450269Displacement of [3H]-BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore.
AID1061889Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID450273Lipophilicity, log P of the compound2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (76.92)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's2 (15.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.62 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]